Low dose Taxol causes mitochondrial dysfunction in actively respiring cancer cells

Area of Science:

• Mitochondrial biology
• Cancer research
• Pharmacology

Background:

• Mitochondria are crucial in cancer development and drug resistance.
• Mitochondrial function is a key target for anticancer drugs.
• Hypoxia, resulting from altered oxygen consumption, impacts cancer progression and treatment response.

Purpose of the Study:

• To investigate the effects of Taxol on mitochondrial respiration, morphology, and dynamics in various cancer cell lines.
• To assess Taxol's impact on mitochondrial ATP production, reactive oxygen species (ROS), membrane potential, and cytochrome c release.
• To compare Taxol's effects on oxidative versus glycolytic cancer cells and noncancer cells.

Main Methods:

• Utilized fluorescence-based measurements to assess mitochondrial function.
• Investigated mitochondrial oxygen consumption, oxidative phosphorylation, and glycolysis.
• Analyzed mitochondrial morphology, dynamics, ATP production, ROS generation, membrane potential, and cytochrome c release.
• Examined cell cycle progression and effects on mitochondria-microtubule interactions.

Main Results:

• Taxol, even at low doses, negatively impacts mitochondria in actively respiring (oxidative) cancer cells.
• Observed increased mitochondrial ROS and cytochrome c release.
• Found suppressed ATP production and oxidative phosphorylation.
• Noted fragmentation of the mitochondrial network and disrupted mitochondria-microtubule linkages.
• These effects were specific to oxidative cancer cells, not glycolytic cancer cells or noncancer cells.

Conclusions:

• Taxol disrupts mitochondrial function in oxidative cancer cells, highlighting mitochondria as a key target.
• The observed mitochondrial dysfunction may contribute to Taxol's anticancer effects.
• Differential sensitivity of oxidative versus glycolytic cancer cells to Taxol's mitochondrial effects warrants further investigation.